American Regent v. Hikma: Tralement® Patent Dispute Ends in Consent Judgment
American Regent, Inc. filed suit against Hikma Pharmaceuticals USA, Inc. in the District of New Jersey asserting five patents covering its Tralement® trace elements injection 4* USP product. The case resolved in 188 days via a consent judgment that enjoins Hikma from infringing the licensed ARI patents while preserving FDA approval pathways.
ANDA patent battle over Tralement® ends with negotiated injunction
American Regent, Inc. (ARI), the holder of five U.S. patents covering its Tralement® (trace elements injection 4*, USP) product in 1 mL single-dose and 5 mL vials, filed suit against Hikma Pharmaceuticals USA, Inc. in the District of New Jersey on April 1, 2025. The action, consolidated with a companion case (2:25-cv-14671), alleged that Hikma’s ANDA filing constituted infringement of the Licensed ARI Patents under the Hatch-Waxman framework.
The dispute concluded on October 6, 2025 — just 188 days after filing — through a consent judgment and stipulated injunction. Under the terms, Hikma and its affiliates are enjoined from making, using, selling, offering to sell, importing, or distributing the accused Hikma product in the United States unless specifically authorized by ARI or permitted under 35 U.S.C. § 271(e)(1). Critically, all underlying claims were dismissed without prejudice and without costs, suggesting the parties reached a confidential settlement agreement that governs the commercial terms.
Resolution in under six months is notably swift for multi-patent Hatch-Waxman litigation, suggesting the parties likely negotiated a licensing or market-entry arrangement early in discovery. The public record does not disclose royalty terms, an authorised-generic arrangement, or a market-entry date for Hikma — all commercially significant details that typically sit within the referenced Settlement Agreement. The court retains jurisdiction to enforce the consent judgment, preserving ARI’s ability to act if Hikma departs from agreed terms.
Filing to Consent Judgment in 188 days
188-day resolution — well under the median ANDA litigation timeline of 2–3 years
Consent judgment with injunction: what the resolution means for both parties
Consent judgment: a negotiated court order with binding force
A consent judgment is a court-entered order reflecting the parties’ agreed resolution — it carries the full enforceability of a judicial ruling without a merits adjudication. Here, the District of New Jersey retains jurisdiction to supervise and enforce the judgment. The dismissal of all claims without prejudice means ARI could theoretically refile if Hikma breaches the underlying Settlement Agreement, providing ARI with ongoing leverage.
Hatch-Waxman consent judgmentWithout prejudice: what the public record does and does not tell us
Claims dismissed without prejudice are not extinguished on the merits — they can be reasserted if circumstances change. In Hatch-Waxman settlements, this structure is standard: it preserves ARI’s right to reinstate infringement claims if Hikma launches before an agreed entry date or outside licensed terms. The confidential Settlement Agreement almost certainly specifies launch windows, royalty terms, or authorised-generic rights — none of which appear in the public record.
Without prejudice dismissalHikma enjoined — but FDA approval pathway preserved
The consent judgment enjoins Hikma from commercialising its trace elements injection 4* product in the U.S. without ARI’s authorisation, consistent with a delayed-entry or licensed-launch structure. Notably, the judgment expressly does not block the FDA from granting final ANDA approval, nor does it prevent Hikma from maintaining its Paragraph IV certification. This carve-out is commercially significant: Hikma retains a regulatory-ready position for a future authorised launch.
Injunction with FDA carve-outARI’s Tralement® patent portfolio gains near-term market protection
The five-patent assertion and resulting injunction suggest ARI sought broad protective coverage for Tralement® against generic entry. With Hikma enjoined and the Settlement Agreement governing future entry, ARI likely secures a defined exclusivity runway. For competitors developing trace elements injection generics, this outcome signals that ARI will actively enforce its portfolio and may require licensing rather than tolerating at-risk launches. The injunction’s reach extends to Hikma affiliates, successors, and assigns.
Protected exclusivity periodFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical company — holder of five Tralement® trace elements injection patentsSearch in Eureka ↗ |
| Defendant | Hikma Pharmaceuticals USA, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for trace elements injection 4*Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | C. KYLE MUSGROVE | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant counsel | CINDY CHANG | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s language — enjoining Hikma ‘from infringing the Licensed ARI Patents’ while simultaneously dismissing all claims without prejudice — reflects a carefully balanced settlement structure. The injunction provides ARI with immediate, court-enforceable protection, while the without-prejudice dismissal preserves litigation optionality if Hikma departs from the Settlement Agreement. The express FDA carve-out is particularly notable: it prevents the consent judgment from being read as a barrier to regulatory approval, consistent with Hatch-Waxman policy favouring eventual generic market entry at an agreed time.
US12150956B2 and four further patents — Tralement® trace elements injection formulations
The five asserted patents — US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2 — collectively cover ARI’s Tralement® (trace elements injection 4*, USP), a parenteral nutrition product administered intravenously. Trace elements injections supply essential micronutrients including zinc, copper, manganese, and selenium to patients who cannot receive adequate nutrition orally. The patents span multiple application families, suggesting layered protection across formulation, method-of-use, and potentially dosage-form claims covering both the 1 mL single-dose and 5 mL multi-dose presentations.
The breadth of the five-patent assertion reflects a strategic effort by ARI to create overlapping IP barriers against generic substitution. In the parenteral nutrition segment, where FDA-approved trace elements products face significant generic ANDA pressure, a robust continuation portfolio substantially elevates the cost and risk of generic entry. Any pharmaceutical company developing a competing trace elements injection 4* ANDA should conduct a thorough freedom-to-operate analysis across the full ARI patent family, including pending continuations that may not yet have published.
Should you run an FTO analysis against ARI’s Tralement® patent portfolio?
Any generic or specialty pharmaceutical company developing a trace elements injection 4* USP product — or any injectable micronutrient formulation targeting similar clinical indications — should treat this case as a prompt to assess FTO exposure. ARI has demonstrated both the willingness to file multi-patent Hatch-Waxman suits and the ability to secure injunctive relief rapidly. With five patents asserted and likely additional continuations pending, the risk perimeter extends well beyond the patents named in this litigation.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map ARI’s full patent family — including granted patents, pending applications, and continuation chains — against your candidate formulation. Eureka’s claim-level analysis identifies specific claim limitations that may read on your product, enabling informed decisions about design-arounds, licensing approaches, or ANDA filing strategy before committing to costly development programmes.
Run a freedom-to-operate analysis on US12150956B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman patent cases in pharmaceutical formulations
Explore comparable Hatch-Waxman infringement actions in the NJ District Court involving injectable pharmaceutical formulations and multi-patent ANDA disputes.
What this case signals for the pharmaceutical trace elements IP landscape
A swift consent judgment with injunction signals ARI’s willingness to enforce its Tralement® portfolio aggressively — and Hikma’s preference for a negotiated entry over protracted litigation.
Five-patent portfolios create high litigation cost for ANDA challengers
ARI asserted five patents across both application and granted patent numbers, substantially raising the cost and complexity of any invalidity or non-infringement defence for Hikma. Generic manufacturers evaluating trace elements injection ANDAs should expect multi-patent assertion strategies and factor early settlement costs into launch economics.
Court-retained jurisdiction creates ongoing enforcement risk post-settlement
The District of New Jersey’s retained jurisdiction to enforce the consent judgment means ARI can seek contempt or other relief without re-filing a new case. For Hikma and similarly situated generic manufacturers, adherence to the confidential settlement terms is essential — any deviation could trigger immediate court action under the existing judgment.
American v Hikma — key questions answered
The case resolved via a consent judgment entered by the District of New Jersey. Hikma was enjoined from infringing ARI’s five Licensed ARI Patents covering Tralement® trace elements injection 4* USP. All claims were dismissed without prejudice and without costs. The court retained jurisdiction to enforce the consent judgment and the underlying Settlement Agreement.
ARI asserted five U.S. patents: US12150956B2, US12150957B2, US11975022B2, US11998565B2, and US11786548B2. These patents collectively cover ARI’s Tralement® (trace elements injection 4*, USP) product in 1 mL single-dose and 5 mL vial presentations. The multi-patent assertion is consistent with a layered continuation filing strategy.
No. The consent judgment expressly preserves the FDA’s ability to grant final approval to Hikma’s ANDA and does not prevent Hikma from filing, modifying, or maintaining a Paragraph IV Certification. This carve-out is standard in Hatch-Waxman settlements and is consistent with a confidential Settlement Agreement that may include a negotiated market-entry date.
Dismissal without prejudice means the underlying infringement claims are not resolved on the merits and could theoretically be reinstated. In Hatch-Waxman practice, this is a standard settlement mechanism: ARI retains the right to refile if Hikma launches before an agreed entry date or outside the terms of the confidential Settlement Agreement. No attorneys’ fees or costs were awarded to either party.
The case was resolved in 188 days from filing on April 1, 2025 to the consent judgment on October 6, 2025. This is notably swift relative to the median Hatch-Waxman litigation timeline, which typically spans two to three years. Early resolution of this length typically suggests the parties negotiated settlement terms — potentially including licensing or authorised-generic arrangements — without entering prolonged discovery or claim construction proceedings.
PatSnap Eureka searches patents and litigation data to answer instantly.